SIR-T GPRC5DxBCMA

SIR-T GPRC5DxBCMA is a bispecific cell therapy currently in discovery-stage development by Angeles Therapeutics. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which is engineered to mimic the natural signaling and activation mechanisms of T-cell receptors (TCRs) rather than the chimeric architecture used in traditional CAR-T therapies. This specific candidate is designed to simultaneously target two antigens frequently overexpressed in multiple myeloma: G-protein coupled receptor family C group 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). By dual-targeting these markers, the therapy aims to enhance tumor recognition and mitigate the risk of relapse driven by antigen escape, a common challenge in single-target cell therapies for plasma cell dyscrasias.